Phio Pharmaceuticals Corp. has announced a significant advancement in its drug development program for PH-762. The U.S. Food and Drug Administration (FDA) has accepted the design of a nonclinical toxicology study, which is required prior to initiating a human pivotal trial. The study is scheduled to commence in the first quarter of 2026. Additionally, Phio is on track to deliver a commercially viable drug product from its U.S. supplier later in 2026, in compliance with the FDA's current Good Manufacturing Practices. The results of the nonclinical study have not yet been presented, as the study has not yet begun.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 278866) on December 23, 2025, and is solely responsible for the information contained therein.